iSpecimen Inc. Research and Development Expense
iSpecimen Inc. (ISPC) reported Research and Development Expense of $1.49 million for the 12-month period ending 2024-12-31, per its 10-K filed 2025-04-14.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2025-04-14
- iSpecimen Inc. research and development expense for fiscal 2024 was $1.49M, a 7.75% decline from fiscal 2023.
- iSpecimen Inc. research and development expense for fiscal 2023 was $1.62M, a 9.86% increase from fiscal 2022.
- iSpecimen Inc. research and development expense for fiscal 2022 was $1.47M, a 67.59% increase from fiscal 2021.
- iSpecimen Inc. research and development expense for fiscal 2021 was $879.24K, a 175.42% increase from fiscal 2020.
| Period end | Research and Development Expense 12 month | Research and Development Expense 12 month as first filed |
|---|---|---|
| 2024-12-31 | $1.49M 10-K · filed 2025-04-14 | |
| 2023-12-31 | $1.62M 10-K · filed 2025-04-14 | |
| 2022-12-31 | $1.47M 10-K · filed 2024-03-13 | |
| 2021-12-31 | $879.24K 10-K/A · filed 2023-03-30 | $295.31K 10-K · filed 2022-03-22 |
| 2020-12-31 | $319.24K 10-K · filed 2022-03-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| FOXO TECHNOLOGIES INC. (FOXO) | United States | $0.000B | -277.71 |
| OneMedNet Corp (ONMD) | $0.042B | ||
| bioAffinity Technologies, Inc. (BIAF) | United States | $0.063B | |
| MAXCYTE, INC. (MXCT) | United States | $0.124B | -3.68 |
| NRC HEALTH (NRC) | United States | $0.450B | 42.50 |
| OmniAb, Inc. (OABI) | United States | $0.698B | -8.05 |
| Absci Corp (ABSI) | United States | $1.775B | -14.92 |
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) | United States | $14.060B | -43.97 |
| Medpace Holdings, Inc. (MEDP) | United States | $17.316B | 30.09 |
| INCYTE CORP (INCY) | United States | $24.855B | 13.14 |